Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan’s 1st DTP-IPV Vaccine Containing Salk Vaccine to Be Available in December: Daiichi Sankyo
November 26, 2015
- Ex-Exec of Iwaki Subsidiary Embezzled 126 Million Yen
November 25, 2015
- Lilly Files Suit to Bar Launch of Sawai’s Evista Generic
November 24, 2015
- Eisai Gives Global Rights for Selective PDE4 Inhibitor E6005 to US Firm
November 24, 2015
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
- Eisai to Transfer Clinical Diagnostic Business in Japan to Sekisui Chemical for 22.4 Billion Yen
November 24, 2015
- AZ, NCC Link for Non-Clinical Research Utilizing Mass Spectrometry Imaging
November 18, 2015
- Supreme Court Supports Patent Term Extension for Avastin
November 18, 2015
- Boehringer Exec Expects AMED’s Positive Impact on Company
November 18, 2015
- Japan Pharma Market Likely to Reach 9.7 Trillion Yen in 2022: Fuji Keizai
November 18, 2015
- Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
- Otsuka Hopes Abilify Maintena Grabs 30% Share in Global Atypical Antipsychotic Market in 2018
November 17, 2015
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
- Bayer Yakuhin Now Marketing Authorization Holder for Claritin
November 16, 2015
- Taiho Files for Japan Approval of Allergy Drug Bilastine
November 16, 2015
- Senju, Gene Techno to Form Capital Tie-Up for Biosimilar Development in Ophthalmology
November 16, 2015
- NHI Prices of Plavix Generics “Actually 43% Rather than 50% Price of Original Product”: Sawai Pharmaceutical President
November 16, 2015
- Japanese Makers Earn Overseas in 1st Half, Japan Sales Up Only Slightly: Tally
November 13, 2015
- OrphanPacific Aims to Achieve Black Ink in 2017
November 13, 2015
- Astellas to Transfer Global Dermatology Portfolio to LEO Pharma
November 12, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…